Viral envelope and virus–cell membrane interface

The viral envelope and virus–cell membrane interface is the structural and functional boundary where enveloped viruses interact with host cells to initiate infection. This interface is primarily composed of a host-derived lipid bilayer embedded with virus-specific glycoproteins that mediate attachment and membrane fusion (White et al., 2008, Critical Reviews in Biochemistry and Molecular Biology). These glycoproteins, such as the HIV-1 gp120/gp41 complex or the Influenza hemagglutinin, undergo significant conformational changes upon binding to host receptors to facilitate the merging of viral and cellular membranes (Harrison, 2008, Nature Structural & Molecular Biology). As a therapeutic target, this interface is the focus of entry inhibitors and fusion inhibitors, which aim to block the very first step of the viral life cycle. Drugs like enfuvirtide prevent the structural transitions of viral proteins required for fusion, while others like docosanol are thought to modify the host membrane to inhibit viral entry (Sadowski et al., 2021, StatPearls). Targeting this interface is a key strategy for treating infections like HIV, RSV, and Influenza, though the high mutability of viral surface proteins often leads to the development of resistance.

Other names

Viral envelopeVirus-host cell interfaceViral fusion machineryViral entry interfaceViral lipid bilayer

Inhibition of viral entry by blocking attachment to host receptors or preventing the conformational changes in viral envelope glycoproteins required for membrane fusion.